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Accepted 16 January 2015; Published online 30 January 2015AbstractObjectives: To determine the effectiveness of interventions designed to prevent or reduce publication and related biases.
Study Design and Setting: We searched multiple databases and performed manual searches using terms related to publication bias and
known interventions against publication bias. We dually reviewed citations and assessed risk of bias. We synthesized results by intervention
and outcomes measured and graded the quality of the evidence (QoE).
Results: We located 38 eligible studies. The use of prospective trial registries (PTR) has increased since 2005 (seven studies, moderate
QoE); however, positive outcome-reporting bias is prevalent (14 studies, low QoE), and information in nonmandatory fields is vague (10
studies, low QoE). Disclosure of financial conflict of interest (CoI) is inadequate (five studies, low QoE). Blinding peer reviewers may
reduce geographical bias (two studies, very low QoE), and open-access publishing does not discriminate against authors from low-
income countries (two studies, very low QoE).
Conclusion: The use of PTR and CoI disclosures is increasing; however, the adequacy of their use requires improvement. The effect of
open-access publication and blinding of peer reviewers on publication bias is unclear, as is the effect of other interventions such as
electronic publication and authors’ rights to publish their results.  2015 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Publication bias; Geographical bias; Trial registration; Open access; Peer review; Conflict of interest1. Introduction
Despite substantial global efforts to increase the publica-
tion of health-related research, about half of clinical studies
remain unpublished [1,2]. As a result, published scientific
literature represents an incomplete and biased subset of total
research findings [3]. Consequently, the nonpublication of
research impedes our ability to make objective and balanced
decisions about patient care and resource allocation. Publi-
cation bias (also sometimes referred to as dissemination
bias) occurs when the publication (or nonpublication) ofConflict of interest: None.
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licenses/by-nc-nd/4.0/).research depends on the nature and origin of the research
and the direction of the results [1,4].
Numerous examples demonstrate the detrimental effect
of publication bias on patient care [5e12] and health expen-
ditures [13]. The case of oseltamivir (Tamiflu) for prevent-
ing complications of influenza, for example, illustrates the
real-world ramifications of publication bias. Billions of dol-
lars were spent worldwide to stockpile oseltamivir based on
a published body of evidence that was missing 60% of pa-
tient data [13]. Likewise, clinical decisions based on biased
bodies of evidence harmed millions of patients who received
rosiglitazone [12], gabapentin [10,11], paroxetine [8,9], ro-
fecoxib [6,7], or reboxetine [14].
Despite examples about the impact of publication bias
and overall evidence about the nonpublication of a large
proportion of research findings, publication bias is difficult
to detect when investigating a specific question of interest.
Statistically, current methods for assessing publication bias
are characterized by low power and strongly rely on the
magnitude of the true treatment effect, the distribution of
sample sizes, and a reasonable number of studies [15].ess article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 The use of clinical trial registries has substantially
increased since 2005; however, publication bias is
still pervasive (the results of many registered trials
are never made available). Likewise, although reg-
istries should deter positive outcome reporting, this
bias is still prevalent and registry entries are often
inadequate for independent systematic reviewers to
fully detect this source of publication bias.
What this adds to what was known?
 Publication bias and selective outcome-reporting
bias represent major threats to the validity of sys-
tematic reviews and reduce our ability to produce
valid conclusions based on a body of evidence.
This review highlights that no empirical studies
of current interventions have shown that they
reduce this bias.
What is the implication and what should change
now?
 Evaluation of the effectiveness of all interventions
implemented to reduce publication or related
biased is urgently required to focus campaigning
and advocacy efforts on those most effective. In
addition, for their potential to reduce publication
bias to be realized, stricter regulation of trial regis-
tries is required, with explicit accountabilities and
responsibilities, as well as detailed requirements
for entries into mandatory fields and penalties for
noncompliance.
Consequently, the absence of a statistically significant cor-
relation or regression does not necessarily indicate the
absence of publication bias. Other methods such as the fun-
nel plot and related imputation methods such as trim and
fill have low interrated reliability or rely on the assumption
that asymmetry is exclusively due to bias [16].
Increased awareness of the harmful and unethical conse-
quences of publication bias has led to the implementation
of several measures to reduce the nonpublication of studies
and its related publication bias. In 2010, Song et al. [1] pub-
lished an updated Health Technology Assessment that
states that publication bias occurs during different stages
of research but mainly before the presentation of findings
at conferences and before the submission of manuscripts
to journals. Based on their literature review, they list several
measures to reduce publication bias that have either been
proposed such as a right to publication or already been im-
plemented such as prospective trial registration, mandatory
sponsor guidelines, and others.
K. Thaler et al. / Journal of CliniTable 1 provides a summary of the potential mechanisms
of measures to reduce publication or related biases as pre-
sented by the Song report. Fig. 1 shows the path of trial
conception through to the dissemination (or nonpublica-
tion) of trial results. The measures identified by Song
et al. are shown in light gray shaded boxes, and their point
of effect on the pathway is indicated by a light gray dashed
line. In this figure, black boxes represent dissemination of
results and dashed gray boxes represent nondissemination
or publication bias.
To date, however, it remains unclear whether any of
these measures achieves its intended goal, that is, to in-
crease the availability of trial results and to reduce publica-
tion bias. Therefore, the objective of our systematic review
was to identify and appraise empirical studies of interven-
tions designed and implemented to prevent or reduce pub-
lication bias to determine their effectiveness.2. Methods
In this review, we concentrated on publication bias in the
context of randomized controlled trials (RCTs) in clinical
medicine and only included studies that directly measured
the effect of an intervention on reducing publication or a
related bias. We used the measures identified by Song
et al. [1] as a classification framework and summarized
our results in terms of the effects on publication bias or
related biases, such as outcome-reporting bias, positive
outcome bias, geographical or language bias, and so forth.
We included any empirical research study of a measure to
reduce publication bias where an analysis was performed
that sought to quantify or determine the success of the inter-
vention in preventing or reducing publication bias or related
biases. Many studies have demonstrated the existence of
publication bias, and these were not the subject of this re-
view. We did not include studies that merely demonstrated
the presence of publication biasdsuch as the number of
conference abstracts of RCTs that were subsequently pub-
lished in full in journals or associations between industry
sponsorship and positive results or delay in publication.
We searched MEDLINE (via PubMed), the Cochrane
Library, EMBASE, CINAHL, PsycINFO, AMED, and
Web of Science. The full search strategy is presented in
‘‘Additional material 1.’’ We used medical subject headings
and key words, focusing on terms for publication bias,
related biases (i.e., ‘‘selection bias’’), and for the known in-
terventions (i.e., ‘‘registry,’’ ‘‘prospective registration,’’
‘‘publishing/ethics,’’ ‘‘disclosure,’’ ‘‘peer review,’’ ‘‘elec-
tronic publishing,’’ ‘‘open access,’’ ‘‘right to publication,’’
‘‘CONSORT statement,’’ ‘‘conflict of interest,’’ ‘‘research
sponsor guidelines,’’ and so forth). We initially searched
sources from inception up to May 2012. In a second stage
in AprileJune 2014, we performed updated and extended
hand and electronic searches using forward and backward
citation and reference tracking of pertinent key references
Table 1. Measures to reduce publication bias
Research sponsors’ guidelines Guidelines such as the EU Clinical Trials Directive, the Declaration of Helsinki, and the
CONSORT Statement have been developed so that researchers can follow the same sets of
standards. Guidelines that stress the importance of reporting both positive and negative
findings can help prevent selective reporting of outcomes.
Prospective trial registration and mandatory
availability of trial results in registry
Prospective registration of trials and mandatory reporting of results within 2 years is required
by US law. This is an attempt to prevent the ‘‘file-drawer’’ problem of unfavorable results
disappearing. Even without regulation to enforce publication of results, trial registries
increase transparency. Since 2005, the ICMJE have applied a policy of accepting only
manuscripts of trials that have been prospectively registered, however, not all medical
journal adhere to the ICMJE policy.
Right to publication Ensuring that researchers, and not funders, have the proprietary right to publish results of
research conducted in their clinics would reduce the ‘‘file-drawer’’ problem of unfavorable
results never being published.
Peer review Targets for changes to the publication process might include the peer review process,
mandatory disclosure of conflict of interest, or electronic publication. Peer reviewers have
been criticized for rejecting manuscripts with negative or null results and for being biased
toward their own country or language and one measure that might reduce this bias is
blinding of peer reviewers.
Disclosure of conflict of interest Disclosure of conflict of interest enables readers to determine whether the authors of a trial
manuscript may have motives to present the results in a more favorable light (and may
increase the readers’ suspicion of reporting biases).
Electronic publication Because of their unlimited size, electronic journals could accept all methodologically sound
manuscripts regardless of thedirectionof the results (reducingpositive outcome-reportingbias).
Open-access policy May mean open access to all trial results or the open-access publishing modeldwhere authors
pay a publishing fee and articles are freely available to all readers. The latter is a method to
counteract the barrier of a ‘‘pay-wall’’ for users of the medical literature.
Abbreviations: CONSORT, Consolidated Standards of Reporting Trials; ICMJE, International Committee of Medical Journal Editors.
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experts in the field of publication bias for their suggestions
of relevant studies. We imported all citations into EndNote
X4 (Thomson Reuters).
We retrieved all results from searches and performed in-
dependent dual review of abstracts and relevant full-text
publications. Disagreements were resolved between the
two reviewers or with a third reviewer. A single reviewer
performed an assessment of the risk of bias of all empirical
studies (low, unclear, or high risk of bias), which was
confirmed by a second reviewer. For RCTs, we used the
Cochrane Collaboration risk of bias tool, assessing ade-
quacy of randomization, allocation concealment, the impact
of attrition, and incomplete reporting [4]. We based the risk
of bias assessment for observational studies on criteria out-
lined by Deeks et al. [18]. For example, we assessed the
comparability of groups and the appropriateness of the
interpretation of statistical analyses.
We classified the interventions into the categories as
listed in Table 1 and presented in Fig. 1. We then summa-
rized the results of the included studies qualitatively.
For each outcome, we graded the quality of the available
evidence (QoE) in a four-part hierarchy based on an
approach devised by the GRADE (Grading of Recommen-
dations Assessment, Development and Evaluation) working
group (high, moderate, low, and very low) [19]. This
grading system reflects our confidence that the true effect
lies close to that of the estimate of the effect. The factors
that influence the QoE for a specific outcome are: the over-
all risk of bias of the studies and suspicion of publication
bias, the consistency of the results (between the studies),the precision of the pooled result, and the directness of
the studies regarding the subject studied, intervention im-
plemented, and outcomes available. Factors that can in-
crease the overall QoE are: when a large effect is present
or a doseeresponse relationship is observed and the nature
and direction of plausible confounding. A single reviewer
graded the evidence and allocated a rating. A second, senior
reviewer confirmed the rating.3. Results
We identified 5,042 citations from searches and reviews
of reference lists and screened 3,749 records, after removal
of duplicates. Fig. 2 documents the disposition of the re-
view process. We located 38 articles that analyzed the
effectiveness of interventions to prevent or reduce publica-
tion bias [20e57]. The included research provides evidence
regarding: prospective trial registration; the peer review
process; disclosure of conflicts of interest (CoIs); and
open-access publishing. We did not locate any evidence
on the other categories of interventions, that is, research
sponsors’ guidelines, right to publication, or electronic pub-
lication. Table 2/Appendix at www.jclinepi.com provides
information on the study design, intervention, results, and
risk of bias rating for all included studies. Most of the
studies we located were cross-sectional. Some were obser-
vational studies that relied on an historical control. Where
randomized trials were available (i.e., for blinded peer re-
view), they were often too small to provide adequate statis-
tical power to detect small but potentially important
differences. The QoE was generally reduced because of
Fig. 1. Process from conception of a clinical trial to dissemination of the results with point of impact of interventions to reduce publication bias.
Interventions to reduce publication bias as classified by Song et al. [1] are shown in light gray boxes. The outcomes of the decision to disseminate
results and their impact on ‘‘publication bias’’ are shown in black boxes (trial results are partially or fully publically available) or in dashed-line
boxes, which represent trial results which are not available (nonpublication, or nondissemination). This is a simplification of a complicated social
and organization system and some aspects of publication bias, such as gray literature and results available in abstract form are not reflected in this
figure.
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from within one medical specialty), or imprecision (where
studies were small and confidence intervals included both a
potential benefit and harm or no effect). Table 2 presents a
summary of the QoE for each intervention.
We begin each results subsection by providing context
about the theoretical background of why each specific mea-
sure could reduce publication bias. We then summarize thenew evidence gained from our systematic review address-
ing the effectiveness of each measure.3.1. Prospective trial registration
3.1.1. Theoretical background
Prospective trial registration has multiple foreseeable
benefits [1]. First, registration of all clinical trials enables
Fig. 2. PRISMA: disposition of the literature.
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make every attempt to include its results in their review. Un-
fortunately, as we have seen in the case of the trials of osel-
tamivir for influenza, merely knowing of the existence of
trials does not always enable reviewers to gain access to
the trial results [13]. A second benefit of prospective trial
registration is that the trial protocols are publically available.
This transparency should discourage (or completely prevent)
cases where trialists change prespecified primary or second-
ary outcomes, sample size calculations, or other methodo-
logical aspects of their trial to present more favorable
results in a final publication. A third benefit of trial registries
is to allow systematic reviewers to easily detect cases where
prespecified outcomes or methodological aspects of trials
are changed and incorporate this knowledge into their sum-
maries of the evidence [4]. Finally, trial registries can act as
repositories for trial results on trial completion.
3.1.2. Evidence about effectiveness
We located 30 studies that evaluated aspects of prospec-
tive trial registration related to publication bias [20e49].
These studies offered data on several key issues: whether
the International Committee of Medical Journal Editors
(ICMJE) policy on accepting only manuscripts of prospec-
tively registered trials has increased the proportion of trials
registered (use of registries); whether prospective trial regis-
tration decreases the proportion of scientific publications
that report different key outcomes or methods than those
initially registered (i.e., discourages selective outcome-
reporting bias); the quality and accuracy of informationcontained in trial registries (i.e., for systematic reviewers
to be able to detect selective outcome-reporting bias if it oc-
curs); and finally, whether the FDA Amendment Act 2007
mandating that trial results be available in registries is
effective.
3.1.2.1. Use of trial registries. Since 2005, the ICMJE
have applied a policy of accepting only manuscripts of tri-
als that have been prospectively registered, however, not all
biomedical journal adhere to the ICMJE policy [20]. Seven
studies indicated that implementation of the ICMJE policy
in 2005 has led to an increase in the proportion of trials that
are prospectively registered (moderate QoE)
[20,23,33,37,39,46,48]. For example, one before and after
study of the trial registry clinicaltrials.gov showed that
the number of registered records in the 6 months around
the implementation of the ICMJE policy in September
2005 increased by 73% from 13,153 to 22,714 [20]. Like-
wise, a cross-sectional analysis of 137 reports of RCTs in
oncology showed that the proportion of registered trials
increased from 0% to 80% between 2002 and 2008 [23],
and a review of RCTs in oncology revealed that the regis-
tration rate increased from 43% to 82% between 2005 and
2009 [39].
3.1.2.2. Discouraging selective outcome-reporting bias.
Fourteen studies of registry entries provide evidence that
the problem of positive outcome-reporting bias still exists,
even for prospectively registered trials (low QoE). Specif-
ically, between 30% and 50% of primary outcomes and
Table 2. Summary of the evidence for interventions to reduce publication bias
Intervention
Number of
studies Summary of evidence
Quality of
evidencea
Research sponsors’ guidelines None No evidence located
Prospective trial registration 30 Studies The use of trial registries has increased since implementation of the ICMJE
policy in 2005
Moderate
Selective outcome-reporting bias persists in 30e65% of published reports of
trials despite registration
Low
In approximately 50% of registry entries, it is not possible for readers/reviewers
to detect outcome-reporting bias due to missing information
Low
Mandatory to enter trial outcome/
results data in registry
1 Study Only 22% of pediatric trials subject to the FDA Amendment Act 2007 had
entered results after 12 months; however, only 10% of trials not subject to the
act had results.
Very low
Right to publication None No evidence located
Peer review 2 Studies Blinding peer reviewers reduces geographical bias against non-US authors Very low
Disclosure of conflict of interest 5 Studies Between 8% and 29% of authors did not reveal any conflict and up to two-thirds
did not fully reveal their financial conflicts of interest
Low
Electronic publication None No evidence located
Open access 1 Study Open-access publishing does not increase geographical bias against authors
from LMIC
Very low
Abbreviations: ICMJE, International Committee of Medical Journal Editors; FDA, Food and Drug Administration; LMIC, low- and middle-income
countries.
a Quality of evidence determined using the GRADE system (Grading of Recommendations Assessment, Development and Evaluation).
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first and last entry of study information in trial registries or
differ between registry entry and journal publication
[22,23,27e30,35,36,40e42,44,47,49].
In one study, it was shown that a noninferiority margin
was specified in only 32% of entries of noninferiority trials
in clinicaltrials.gov [27]. The very existence of these
studies, however, illustrates the improved ability of system-
atic reviewers to detect this bias when it occurs (e.g.,
through the ‘‘archive feature’’ of clinicaltrials.gov).
Although we know selective outcome reporting still oc-
curs, it may have conceivably been reduced by prospective
trial registration. To quantify this comparison, Rasmussen
et al [23] conducted a cross-sectional analysis of 137 pub-
lished reports of 115 distinct RCTs that evaluated the 25
oncology drugs newly approved for use by the FDA in
the period 2000e2005 and compared those that were pro-
spectively registered with those not registered. All articles
were published between 1996 and 2008. The authors did
not find any difference between the likelihood of regis-
tered studies to favor the test drug as compared with non-
registered RCTs [odds ratio (OR) 1.11; 95% confidence
interval (CI): 0.44, 2.80]. These results indicate that the
use of trial registries is increasing; however, no effect on
reducing, positive outcome-reporting bias could be seen
(very low QoE).
3.1.2.3. Detecting selective outcome-reporting bias. Pro-
spective trial registries could assist systematic reviewers
or other independent persons to detect selective
outcome-reporting bias by allowing them to cross-check
planned primary and secondary outcomes and potential
subgroup analyses with those presented in the publications
of result of trials. For this to be possible, the data in trialregistries must be accurate and complete. We located 10
studies that indicate that many entries in trial registries
contain missing or faulty information regarding outcomes
and important methodological aspects of trials (low QoE)
[20,22,24,25,30,31,34,38,43,45]. Nonetheless, the report-
ing of methods in registered trials is probably better than
that of nonregistered trials (one study, very low QoE) [26].
In detail, the largest cross-sectional study of 7,515 regis-
tered clinical trials in clinicaltrials.gov conducted in 2007
indicated that only 66% provided details on the primary
outcome and only 56% described secondary outcomes
[24]. Records entered by the top 10 pharmaceutical com-
panies around the time of the implementation of the
ICMJE compulsory trial registration policy were even
more imprecise: in 657 records only 31% provided specific
information on the primary outcome including the measure
and the time frame [20]. When details of primary and sec-
ondary outcomes are entered into registries, the entries are
often too vague for them to be useful for systematic re-
viewers to retrospectively detect bias. For example, several
studies showed that the reporting of outcome measures and
time for follow-up of outcomes was vague [24,30,31]. Ex-
amples include: providing an outcome such as ‘‘anxiety’’
but no measurement scale or providing a measurement
(specific rating scale) but no time frame or method of anal-
ysis (e.g., categorical, change from baseline, period of
follow-up).
A similar pattern was seen in the reporting of methodo-
logical aspects of trials in registries. One study that evalu-
ated the adequacy of reporting of key methodological study
details in 265 records of RCTs retrieved from the seven reg-
istries accessible through the World Health Organization
meta-registry International Clinical Trials Registry Plat-
form (WHO ICTRP) search portal (which at that time
798 K. Thaler et al. / Journal of Clinical Epidemiology 68 (2015) 792e802consisted of clinicaltrials.gov plus six primary registries
from Australia, China, India, Germany, ISRCTN, and the
Netherlands) showed that most records provided no useful
information or insufficient detail on allocation concealment
(98%), blinding (86%), or harms (90%) [25]. Explicit re-
porting of sample size calculations was adequate in only
1% of entries. In general, the Australian and Indian regis-
tries had a higher proportion of adequate reporting of
methods, and these registries also provided specific fields
for most of the methodological items assessed. This indi-
cates that specific questions regarding trial methods are
necessary to ensure that the information in the registry is
usable for systematic reviewers.
Despite the fact that many registry entries contain vague
information on outcomes or little information on trial
methods, they may still be better than the information avail-
able for nonregistered trials. A cross-sectional study of 144
RCTs published in 55 journals compared the adequacy of
methodological details such as participant flow and
randomization implementation [26]. Reporting was signifi-
cantly better in publications of RCTs that had been pro-
spectively registered (participant flow: 76% vs. 38%,
randomization: 48% vs. 22%). Similarly, where available,
the reporting of methods was generally more detailed in
registry entries than in the associated publications [42,45].
3.1.2.4. Mandatory availability of results. One study spe-
cifically compared the availability of results in the
clinicaltrials.gov registry for pediatric trials subject to the
FDA Amendments Act [32]. Of the 738 trials that were
located and were subject to mandatory reporting, only
22% had reported results after 12 months. This is compared
with 10% of trials not subject to mandatory reporting (QoE
is very low).3.2. Changes in the peer review process
3.2.1. Theoretical background
The role of the peer reviewer is to decide on the suitability
of a manuscript for publication. The aim was to improve the
quality of scientific articles by engaging an ‘‘expert’’ to re-
view the work, thus preventing the publication of manu-
scripts with flawed methodology or results [1]. Critics of
the peer-reviewing process claim that it increases bias
because reviewers favor manuscripts from well-known au-
thors or from institutions within their own country
(geographical bias) [58,59]. Likewise, peer reviewers may
discriminate against women (gender bias) [60].3.2.2. Evidence of effectiveness
We located two studies where blinded peer review had
been compared with anonymous review, and the effect on
geographical and gender bias was analyzed [50,51]. Many
studies of blinded peer reviewers that focused on accep-
tance of manuscripts in general or on quality or speed ofreviewing in general were not included in this review
[61e64].
3.2.2.1. Blinded peer review to reduce geographical bias.
Two studies (one small randomized trial [51] and one large
before and after study [50]) indicated that blinding peer re-
viewers reduced geographical bias (very low QoE).
The largest study compared the acceptance of 67,273 ab-
stracts submitted to the American Heart Association’s
annual Scientific Sessions meeting in 2000 and 2001, when
reviewers were aware of the name and institution of submit-
ting authors, with the years 2002 through 2004 when ab-
stracts were submitted anonymously [50]. Blinding of the
peer review process significantly reduced the likelihood
of preferential acceptance of abstracts from US authors,
from countries with English as the official language, and
from prestigious institutions (P ! 0.001 for all compari-
sons). The acceptance rate of abstracts from women or
men was equal for both open and blinded peer reviewers.
In contrast, one smaller randomized trial of blinded peer re-
view of 40 manuscripts submitted to the journal Dermato-
logic Surgery failed to detect significant differences
between the blinded and unblinded reviewers on geograph-
ical bias: no significant differences were detected between
rates of recommendations to accept, accept with revisions,
or reject manuscripts from US or non-US authors [51]. Un-
fortunately, this trial was underpowered to detect a small
but important difference for this outcome.3.3. Disclosure of CoI
3.3.1. Theoretical background
Many studies have shown that financial CoIs lead au-
thors to favor the drugs produced by certain pharmaceutical
companies and present a biased view of the scientific evi-
dence for therapies or to make recommendations that favor
certain drugs [54,65e67]. We did not include studies in this
review that showed that CoI leads to biased research results
or guideline recommendations or studies reporting on the
policies of journals or organizations on disclosures of CoIs.
In this section, we summarize the evidence that an imple-
mented CoI policy is successful in revealing actual
conflicts.3.3.2. Accuracy of disclosures of CoI
3.3.2.1. Evidence of effectiveness. We located five studies
that consistently showed that despite policies requiring au-
thors and guideline panel members to disclose financial
conflicts, between 8% and 29% did not reveal any conflict
and up to two-thirds did not fully reveal their financial CoIs
[52e56]. The authors of the studies cross-checked the dec-
larations of CoI with publically available information on
the transfer of funds from pharmaceutical companies to
doctors (e.g., Dollars for Docs) or from registries of patent
applications or previous journal articles from the same
799K. Thaler et al. / Journal of Clinical Epidemiology 68 (2015) 792e802authors with declarations (see Table 2/Appendix at www.
jclinepi.com) for details. The QoE is low.
3.4. Open access
3.4.1. Theoretical background
‘‘Open access’’ describes free access for all readers to
publications of clinical trials in scientific journals (a system
where users of the scientific literature have unlimited ac-
cess to publications without paying subscription fees to
the publishers of journals). To fund open-access journals,
authors must pay ‘‘publication charges.’’ Open-access pub-
lishing might reduce publication bias because more space is
available in open-access journals for publishing negative
and nonsignificant results. On the other hand, moving the
burden of payment to the authors of publications may
worsen the problem of publication bias if it acts as a barrier
to authors deciding to publish trial results. Costs for authors
are usually between one and two thousand Euros, and jour-
nals often offer discounts for authors from developing
countries. Several funders of clinical research in Europe
mandate open access to the results of studies that they
sponsor and provide funds for the publishing fee [1]. For
readers of the literature, open access obviously provides
more information for less cost.
3.4.2. Open-access publishing and geographical bias
3.4.2.1. Evidence of effectiveness. One study provided two
analyses that sought to determine whether authors from
low- or middle-income countries are discouraged from pub-
lishing in open-access journals (a cross-sectional compari-
son of journal types and a beforeeafter analysis of two
journals that implemented open-access publishing) [57].
The results are conflicting and very imprecise; however,
they indicate that open-access publishing does not increase
geographical bias (very low QoE). In detail, the beforee
after analysis of 485 articles from the two open-access jour-
nals (comparing the nature of articles before and after the
change in policy) did not show any significant difference
for authors from developing countries (OR 1.33; 95% CI:
0.7, 2.52). In contrast, in the cross-sectional comparison
of four different infectious diseases journals at the same
point in time (two subscription payers and two with
open-access publishing fees of 1,230 US dollars), signifi-
cantly fewer articles written by authors from developing
countries were published in the journals with publication
fees compared with the journals without publication
charges (OR 0.25; 95% CI: 0.15, 0.41). This result is likely
to be due to other confounding factors related to the differ-
ences between the journals.4. Discussion
The research and scientific community has been aware
of and calling for solutions to address the problem ofpublication bias for many decades [68,69]. In 2010, Song
et al., [1] identified several possible interventions that
may reduce publication bias. To our knowledge, this is
the first systematic review that sought to synthesize all
the available empirical evidence for the effectiveness of
these interventions. We located studies evaluating the suc-
cess of only four measures, and the results of the studies
we located indicate that we have made progress in the over-
all battle against publication bias but still have much work
ahead. The only conclusions that we can support with low
or moderate ratings for the quality of the body of evidence
is that although the use of clinical trial registries has sub-
stantially increased since the ICMJE policy change in
2005, the problem of nonpublication of trial results and
positive outcome-reporting is still pervasive and the data
available to reviewers in registries are often not adequate
for independent systematic reviewers to recognize this bias.
Likewise, the evidence suggests that blinding peer re-
viewers can reduce geographical bias against non-US au-
thors; on the one hand, this indicates a real potential to
reduce related biases; on the other hand, the potential of
blinding peer reviewers to impact on the larger problem
of publication bias is unclear. We did not locate any direct
evidence comparing the rates of declarations of CoI over
time or a direct connection between CoI and a reduction
in selective outcome reporting, for example; however,
studies between 2006 and 2012 show a consistent and
persistent pattern of inadequate declaration of financial
CoIs. We found no studies on: research sponsors’ guide-
lines; right to publication; or electronic publication.
This review has some limitations. Initially, we concen-
trated our searches on databases; however, it soon became
clear that in this complex field, the yield from electronic
searches alone would be inadequate. We therefore extended
our searches in a second phase to include snowballing tech-
niques and approached experts for suggestions of eligible
studies, as suggested by Greenhalgh and Peacock [17] for
systematic reviews of complex evidence. Nonetheless, we
cannot be sure that we have detected every study of an
intervention to reduce publication bias. Another criticism
of our review might be that we did not include studies of
interventions such a blinded peer review or disclosure of
CoI where the measured outcome was not a reduction in
bias. We used a ‘‘chain of evidence’’ approach and deter-
mined that an improvement in the quality of peer reviews
or an increase in citation rates of open-access articles did
not constitute a link on the chain to reducing publication
bias. In comparison, as shown in Fig. 1, we included many
studies on the completeness of trial registries or their up-
take as registries represent an increasingly crucial link in
the pathway of clinical trial results publication. Likewise,
the success of CoI disclosure is important in evaluating
its ability to decrease publication bias.
The evidence available on the effectiveness of interven-
tions is limited because it is difficult to design and conduct
good trials or natural experiments to test many of the
800 K. Thaler et al. / Journal of Clinical Epidemiology 68 (2015) 792e802interventions suggested by commentators to reduce publi-
cation bias (e.g., changes of whole systems like ethic com-
missions or changes to national regulations/laws).
Nonetheless, some interventions that are often suggested
would be amenable to testing in well-conducted studies.
For example, one could compare the reporting of results
including the accuracy of reporting of primary and second-
ary outcomes in open-access journals compared with
subscription journals. Likewise, we could compare the
availability of negative or nonsignificant results in open-
access journals. We could analyze how many trial results
become public before and after a change to funding or
ethics commission rules. Likewise, we could more thor-
oughly analyze the effect of interventions to the peer review
system on biases such as outcome-reporting or geograph-
ical bias. It seems reasonable that we, as advocates and
practitioners of evidence-based medicine, would base our
campaigns for specific measures to reduce publication bias
on a reasonable level of evidence for their effectiveness.
A second implication of this review is that the one inter-
vention that has been successful in its uptake (trial regis-
tries) is unfortunately weakened by lack of mandatory
fields and lack of regulation to ensure that all data provided
are complete and accurate and not altereddeither during
the course of a trial or after trial completion but before pub-
lication. In addition to mandating their use, responsibility
for the enforcement of the quality of information entered
into trial registries is required, as well as consideration of
increasing the number of compulsory fields. We recom-
mend that fully complete data in the mandatory fields of
a trial registry should also be a prerequisite for ethic com-
mission approval, for being considered for publication, and
of funding for future clinical trials. Furthermore, it is neces-
sary that there is one registry to find all conducted trials,
such as the WHO ICTRP, where each trial has a unique
identifier number. The impact of the policy of mandatory
reporting of results of registered trials within 1 year of their
completion, as required by US law [70], needs to be evalu-
ated further [43].
Lastly, we did not locate any evidence regarding the
mandatory disclosure of all trial data and in which format
this data should be available. Many researchers now
contend that this would be the ultimate panacea for the
problem of publication bias, allowing independent persons
to evaluate, interpret, and summarize the results of clinical
trials [71].Acknowledgments
This report is the result of work done in the UN-
COVER project. The consortium that contributed to the
UNCOVER project includes persons from the Austrian
Institute of Technology Department for Foresight & Pol-
icy Development (Coordinating partner) and the UNC
University of North Carolina at Chapel Hill GillingsSchool of Global Public Health. A second report from
this work package that provides a thematic analysis and
stakeholder interviews regarding barriers and facilitators
of measures to reduce publication bias has been pub-
lished [72].
The authors thank Evelyn Auer and Julia Schober for
administrative support on this project and the peer reviewer
and experts who we contacted for their advice.
Authors’ contributions: All authors contributed to
designing the review, participated in reviewing abstracts
and full publications, synthesized the results, and contrib-
uted to writing the manuscript. In addition, K.T. was
responsible for the review team, M.G.V.N. and I.K. per-
formed the electronic searches, and C.K. coordinated the
work package for this project.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.jclinepi.2015.01.008.References
[1] Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al.
Dissemination and publication of research findings: an updated re-
view of related biases. Health Technol Assess 2010;14. iii, ix-xi,
1-193.
[2] Galsworthy MJ, Hristovski D, Lusa L, Ernst K, Irwin R,
Charlesworth K, et al. Academic output of 9 years of EU investment
into health research. Lancet 2012;380:971e2.
[3] Chan AW, Song F, Vickers A, Jefferson T, Dickersin K,
Gotzsche PC, et al. Increasing value and reducing waste: addressing
inaccessible research. Lancet 2014;383:257e66.
[4] Higgins JPT, Green S, editors. Cochrane handbook for systematic
reviews of interventions version 5.1.0 [updated March 2011].
Oxford, UK: The Cochrane Collaboration; 2011: Available at:
http://handbook.cochrane.org/. Accessed Oct 3, 2014.
[5] Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R.
Risk of cardiovascular events and celecoxib: a systematic review
and meta-analysis. J R Soc Med 2006;99(3):132e40.
[6] Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM.
Pooled analysis of rofecoxib placebo-controlled clinical trial data:
lessons for postmarket pharmaceutical safety surveillance. Arch
Intern Med 2009;169:1976e85.
[7] Psaty BM, Kronmal RA. Reporting mortality findings in trials of ro-
fecoxib for Alzheimer disease or cognitive impairment: a case study
based on documents from rofecoxib litigation. JAMA 2008;299:
1813e7.
[8] Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A,
Boddington E. Selective serotonin reuptake inhibitors in childhood
depression: systematic review of published versus unpublished data.
Lancet 2004;363:1341e5.
[9] Jureidini JN, McHenry LB, Mansfield PR. Clinical trials and drug
promotion: selective reporting of study 329. Int J Risk Saf Med
2008;20:73e81.
[10] Vedula SS, Goldman PS, Rona IJ, Greene TM, Dickersin K. Imple-
mentation of a publication strategy in the context of reporting
biases. A case study based on new documents from Neurontin liti-
gation. Trials 2012;13:136.
[11] Vedula SS, Bero L, Scherer RW, Dickersin K. Outcome reporting in
industry-sponsored trials of gabapentin for off-label use. N Engl J
Med 2009;361:1963e71.
801K. Thaler et al. / Journal of Clinical Epidemiology 68 (2015) 792e802[12] Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-
analysis of risk for myocardial infarction and cardiovascular mortal-
ity. Arch Intern Med 2010;170(14):1191e201.
[13] Jefferson T, Jones MA, Doshi P, Del Mar CB, Heneghan CJ,
Hama R, et al. Neuraminidase inhibitors for preventing and treating
influenza in healthy adults and children. Cochrane Database Syst
Rev 2012;CD008965.
[14] Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M,
Kaiser T, et al. Reboxetine for acute treatment of major depression:
systematic review and meta-analysis of published and unpublished
placebo and selective serotonin reuptake inhibitor controlled trials.
BMJ 2010;341:c4737.
[15] Macaskill P, Walter SD, Irwig L. A comparison of methods to detect
publication bias in meta-analysis. Stat Med 2001;20:641e54.
[16] Terrin N, Schmid CH, Lau J. In an empirical evaluation of the fun-
nel plot, researchers could not visually identify publication bias. J
Clin Epidemiol 2005;58:894e901.
[17] Greenhalgh T, Peacock R. Effectiveness and efficiency of search
methods in systematic reviews of complex evidence: audit of pri-
mary sources. BMJ 2005;331:1064e5.
[18] Deeks JJ, Dinnes J, D’Amico R, Sowden AJ, Sakarovitch C, Song F,
et al. Evaluating non-randomised intervention studies. Health Tech-
nol Assess 2003;7. iii-x, 1-173.
[19] Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y,
Schunemann HJ. What is ‘‘quality of evidence’’ and why is it
important to clinicians? BMJ 2008;336:995e8.
[20] Zarin DA, Tse T, Ide NC. Trial registration at ClinicalTrials.gov be-
tween May and October 2005. N Engl J Med 2005;353:2779e87.
[21] Sekeres M, Gold JL, Chan AW, Lexchin J, Moher D, Van
Laethem ML, et al. Poor reporting of scientific leadership informa-
tion in clinical trial registers. PLoS One 2008;3(2):e1610.
[22] Mathieu S, Boutron I, Moher D, Altman DG, Ravaud P. Comparison
of registered and published primary outcomes in randomized
controlled trials. JAMA 2009;302:977e84.
[23] Rasmussen N, Lee K, Bero L. Association of trial registration with
the results and conclusions of published trials of new oncology
drugs. Trials 2009;10:116.
[24] Ross JS, Mulvey GK, Hines EM, Nissen SE, Krumholz HM. Trial
publication after registration in ClinicalTrials.Gov: a cross-
sectional analysis. PLoS Med 2009;6(9):e1000144.
[25] Reveiz L, Chan AW, Krleza-Jeric K, Granados CE, Pinart M,
Etxeandia I, et al. Reporting of methodologic information on
trial registries for quality assessment: a study of trial records
retrieved from the WHO search portal. PLoS One 2010;5(8):
e12484.
[26] Reveiz L, Cortes-Jofre M, Asenjo Lobos C, Nicita G, Ciapponi A,
Garcia-Dieguez M, et al. Influence of trial registration on reporting
quality of randomized trials: study from highest ranked journals. J
Clin Epidemiol 2010;63:1216e22.
[27] Dekkers OM, Soonawala D, Vandenbroucke JP, Egger M. Reporting
of noninferiority trials was incomplete in trial registries. J Clin Epi-
demiol 2011;64:1034e8.
[28] Huic M, Marusic M, Marusic A. Completeness and changes in
registered data and reporting bias of randomized controlled trials
in ICMJE journals after trial registration policy. PLoS One 2011;
6(9):e25258.
[29] Viergever RF, Ghersi D. The quality of registration of clinical trials.
PLoS One 2011;6(2):e14701.
[30] Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The Clinical-
Trials.gov results databasedupdate and key issues. N Engl J Med
2011;364:852e60.
[31] Jones CW, Platts-Mills TF. Quality of registration for clinical trials
published in emergency medicine journals. Ann Emerg Med 2012;
60(4):458e464 e1.
[32] Prayle AP, Hurley MN, Smyth AR. Compliance with mandatory re-
porting of clinical trial results on ClinicalTrials.gov: cross sectional
study. BMJ 2012;344:d7373.[33] Reveiz L, Bonfill X, Glujovsky D, Pinzon CE, Asenjo-Lobos C,
Cortes M, et al. Trial registration in Latin America and the Carib-
bean’s: study of randomized trials published in 2010. J Clin Epide-
miol 2012;65:482e7.
[34] Ross JS, Tse T, Zarin DA, Xu H, Zhou L, Krumholz HM. Publica-
tion of NIH funded trials registered in ClinicalTrials.gov: cross
sectional analysis. BMJ 2012;344:d7292.
[35] Shamliyan T, Kane RL. Clinical research involving children: regis-
tration, completeness, and publication. Pediatrics 2012;129(5):
e1291e300.
[36] Smith HN, Bhandari M, Mahomed NN, Jan M, Gandhi R. Compar-
ison of arthroplasty trial publications after registration in Clinical-
Trials.gov. J Arthroplasty 2012;27(7):1283e8.
[37] van de Wetering FT, Scholten RJPM, Haring T, Clarke M, Hooft L.
Trial registration numbers are underreported in biomedical publica-
tions. PLoS One 2012;7(11):e49599.
[38] Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N, Kaiser T.
Impact of document type on reporting quality of clinical drug trials:
a comparison of registry reports, clinical study reports, and journal
publications. BMJ 2012;344:d8141.
[39] You B, Gan HK, Pond G, Chen EX. Consistency in the analysis and
reporting of primary end points in oncology randomized controlled
trials from registration to publication: a systematic review. J Clin
Oncol 2012;30:210e6.
[40] Hannink G, Gooszen HG, Rovers MM. Comparison of registered
and published primary outcomes in randomized clinical trials of sur-
gical interventions. Ann Surg 2013;257(5):818e23.
[41] Li XQ, Yang GL, Tao KM, Zhang HQ, Zhou QH, Ling CQ. Com-
parison of registered and published primary outcomes in random-
ized controlled trials of gastroenterology and hepatology. Scand J
Gastroenterol 2013;48(12):1474e83.
[42] Liu JP, Han M, Li XX, Mu YJ, Lewith G, Wang YY, et al. Prospec-
tive registration, bias risk and outcome-reporting bias in randomised
clinical trials of traditional Chinese medicine: an empirical method-
ological study. BMJ Open 2013;3(7).
[43] Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I,
Ravaud P, et al. Timing and completeness of trial results posted at
ClinicalTrials.gov and published in journals. PLoS Med 2013;
10(12):e1001566.
[44] Rosenthal R, Dwan K. Comparison of randomized controlled trial
registry entries and content of reports in surgery journals. Ann Surg
2013;257(6):1007e15.
[45] Tharyan P, George AT, Kirubakaran R, Barnabas JP. Reporting of
methods was better in the Clinical Trials RegistrydIndia than in In-
dian journal publications. J Clin Epidemiol 2013;66:10e22.
[46] Babu AS, Veluswamy SK, Rao PT, Maiya AG. Clinical trial regis-
tration in physical therapy journals: a cross-sectional study. Phys
Ther 2014;94:83e90.
[47] Killeen S, Sourallous P, Hunter IA, Hartley JE, Grady HL. Registra-
tion rates, adequacy of registration, and a comparison of registered
and published primary outcomes in randomized controlled trials
published in surgery journals. Ann Surg 2014;259(1):193e6.
[48] Shamliyan TA, Kane RL. Availability of results from clinical
research: failing policy efforts. J Epidemiol Glob Health 2014;
4(1):1e12.
[49] Viergever RF, Karam G, Reis A, Ghersi D. The quality of registra-
tion of clinical trials: still a problem. PLoS One 2014;9(1).
[50] Ross JS, Gross CP, Desai MM, Hong Y, Grant AO, Daniels SR, et al.
Effect of blinded peer review on abstract acceptance. JAMA 2006;
295:1675e80.
[51] Alam M, Kim NA, Havey J, Rademaker A, Ratner D, Tregre B,
et al. Blinded vs. unblinded peer review of manuscripts submitted
to a dermatology journal: a randomized multi-rater study. Br J Der-
matol 2011;165:563e7.
[52] Mayer S. Declaration of patent applications as financial interests: a
survey of practice among authors of papers on molecular biology in
nature. J Med Ethics 2006;32:658e61.
802 K. Thaler et al. / Journal of Clinical Epidemiology 68 (2015) 792e802[53] Okike K, Kocher MS, Wei EX, Mehlman CT, Bhandari M. Accu-
racy of conflict-of-interest disclosures reported by physicians.
N Engl J Med 2009;361(15):1466e74.
[54] Wang AT, McCoy CP, Murad MH, Montori VM. Association between
industry affiliation and position on cardiovascular risk with rosiglita-
zone: cross sectional systematic review. BMJ 2010;340:1344.
[55] Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of finan-
cial conflicts of interest among panel members producing clinical
practice guidelines in Canada and United States: cross sectional
study. BMJ 2011;343:5621.
[56] Norris SL, Holmer HK, Ogden LA, Burda BU, Fu R. Characteristics
of physicians receiving large payments from pharmaceutical com-
panies and the accuracy of their disclosures in publications: an
observational study. BMC Med Ethics 2012;13:24.
[57] Liyanage SS, Raina Macintyre C. Do financial factors such as author
page charges and industry funding impact on the nature of published
research in infectious diseases? Health Info Libr J 2006;23:214e22.
[58] Link AM. US and non-US submissions. An analysis of reviewer
bias. JAMA 1998;280:246e7.
[59] Opthof T, Coronel R, Janse MJ. The significance of the peer review
process against the background of bias: priority ratings of reviewers
and editors and the prediction of citation, the role of geographical
bias. Cardiovasc Res 2002;56:339e46.
[60] Gilbert JR, Williams ES, Lundberg GD. Is there gender bias in JA-
MA’s peer review process? JAMA 1994;272:139e42.
[61] van Rooyen S, Godlee F, Evans S, Smith R, Black N. Effect of
blinding and unmasking on the quality of peer review: a randomized
trial. JAMA 1998;280:234e7.
[62] van Rooyen S, Godlee F, Evans S, Black N, Smith R. Effect of open
peer review on quality of reviews and on reviewers’ recommenda-
tions: a randomised trial. BMJ 1999;318:23e7.[63] Van Rooyen S, Godlee F, Evans S, Smith R, Black N. Effect of
blinding and unmasking on the quality of peer review. J Gen Intern
Med 1999;14:622e4.
[64] Schroter S, Black N, Evans S, Carpenter J, Godlee F, Smith R. Ef-
fects of training on quality of peer review: randomised controlled
trial. BMJ 2004;328:673: Available at http://onlinelibrary.wiley.
com/o/cochrane/clcentral/articles/643/CN-00769643/frame.html.
[65] Bekelman JE, Li Y, Gross CP. Scope and impact of financial con-
flicts of interest in biomedical research: a systematic review. JAMA
2003;289:454e65.
[66] Jorgensen AW, Hilden J, Gotzsche PC. Cochrane reviews compared
with industry supported meta-analyses and other meta-analyses of
the same drugs: systematic review. BMJ 2006;333:782.
[67] Lundh A, Sismondo S, Lexchin J, Busuioc Octavian A, Bero L. In-
dustry sponsorship and research outcome. Cochrane Database Syst
Rev 2012;MR000033: Available at http://onlinelibrary.wiley.com/
doi/10.1002/14651858.MR000033.pub2/abstract. Accessed March
15, 2014.
[68] Chalmers I, Moher D. Publication bias. Lancet 1993;342:1116.
[69] Dickersin K, Min YI. Publication bias: the problem that won’t go
away. Ann N Y Acad Sci 1993;703:135e46. discussion 146e8.
[70] ClinicalTrials.gov. 2012 [updated August 2012; cited 2012
September 3]. Available at http://clinicaltrials.gov/ct2/about-site/
history. Accessed September 3, 2012.
[71] Gotzsche PC. Why we need easy access to all data from all clinical
trials and how to accomplish it. Trials 2011;12:249.
[72] Kien C, Nussbaumer B, Thaler KJ, Van Noord MG, Wagner P,
Gartlehner G. Barriers to and facilitators of interventions to
counterpublication bias: thematic analysis of scholarly articles
and stakeholderinterviews. BMC Health Services Research 2014;
14:551.
